These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17301972)

  • 21. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
    Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
    Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Ricksten A; Palmqvist L; Johansson P; Andreasson B
    Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
    [No Abstract]   [Full Text] [Related]  

  • 24. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
    Medeiros BC; Zhang T; Lipton JH; Kamel-Reid S
    Am J Hematol; 2007 Apr; 82(4):293-4. PubMed ID: 17013813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral vertebral artery dissection and essential thrombocythemia with JAK2 mutation.
    Verdure P; Lefaucheur R; Guegan-Massardier E; Triquenot-Bagan A; Gerardin E; Maltête D
    Rev Neurol (Paris); 2012 Jun; 168(6-7):543-4. PubMed ID: 22677324
    [No Abstract]   [Full Text] [Related]  

  • 30. Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.
    Ohyashiki K; Ito Y; Hori K; Sato K; Makino T; Ohyashiki JH
    Leukemia; 2007 Jul; 21(7):1570-1. PubMed ID: 17392820
    [No Abstract]   [Full Text] [Related]  

  • 31. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis.
    De Stefano V; Rossi E; Za T; Ciminello A; Betti S; Luzzi C; Leone G; Chiusolo P
    Am J Hematol; 2011 Jun; 86(6):526-8. PubMed ID: 21594892
    [No Abstract]   [Full Text] [Related]  

  • 32. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
    Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
    Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two cases of concurrent development of essential thrombocythemia with chronic lymphocytic leukemia, one related to clonal B-cell lymphocytosis, tested by array comparative genomic hybridization.
    Kim H; Jang W; Shin S; Park J; Kim M; Kim Y; Han K; Lee GD; Won H; Yang YJ
    Int J Hematol; 2015 Jun; 101(6):612-9. PubMed ID: 25491494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of femoral fracture in a patient with essential thrombocythemia treated with plateletpheresis and intramedullary rod fixation, followed by hydroxyurea: a case report.
    Edlich RF; Long WB; Cochran AA; Kelley AR; Woode DR; Greene JA; Takahashi GW
    Am J Emerg Med; 2008 Jun; 26(5):636.e1-3. PubMed ID: 18534315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
    Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
    Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
    Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
    Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
    [No Abstract]   [Full Text] [Related]  

  • 40. [Essential thrombocythemia: molecular pathophysiology and treatment].
    Dan K
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():326-9. PubMed ID: 23133976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.